Could senolytics be holding the cure for Alzheimer’s?

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

For years, scientists have assumed amyloid plaques caused neurodegenerative conditions like Alzheimer’s disease. Now the consensus appears to be shifting, and the implications for senolytics could shake an entire industry.

The story went like this: with age, junk protein clumps called beta-amyloids accumulate as plaques in the brain; stripping neuronal function as they grow, causing memory loss and enveloping the mind in an expanding blanket of static. This was Alzheimer’s disease, and curing it was just a matter of removing the plaques.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Ben Turner

Staff Writer

Ben Turner is a writer and journalist based in London. He graduated in 2015 with a Master’s degree in Physics. He is particularly interested in the translation of early scientific discoveries into cutting-edge tech.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Beauty giant and supplement startup both chase skin aging

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE